Apoptotic signaling: Beyond cell death
- PMID: 37988794
- DOI: 10.1016/j.semcdb.2023.11.002
Apoptotic signaling: Beyond cell death
Abstract
Apoptosis is the best described form of regulated cell death, and was, until relatively recently, considered irreversible once particular biochemical points-of-no-return were activated. In this manuscript, we examine the mechanisms cells use to escape from a self-amplifying death signaling module. We discuss the role of feedback, dynamics, propagation, and noise in apoptotic signaling. We conclude with a revised model for the role of apoptosis in animal development, homeostasis, and disease.
Keywords: Anastasis; Apoptosis; Caspase; Feedback in apoptosis; Regulated cell death.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have organizational affiliations, stock ownership, and research support to disclose. D.J.M. is a member of the Board of Scientific Counselors for the National Cancer Institute; has 5% equity in Mor Bio, a subsidiary of Inceptor Bio, which is a cellular immunotherapy company; and has 20% equity in Anastasis Biotechnology Corporation. The authors have patent filings to disclose: Modulation of Anastasis, UCSB Case Number 2020–062–2, US Patent found in United States Provisional Patent Application Number 63/029,380, entitled “Methods of Modulating Anastasis,” filed May 22, 2020; Detection of Anastasis, UCSB Case Number 2020–62–1, found in US Patent United States Provisional Patent Application Number 63/029,358, entitled “Methods of Detecting Anastasis,” filed May 22, 2020; US provisional application no. 63/014,049 entitled “Stimulating Phagocytosis of Cancer Cells by Activating Rac in Macrophages” filed on April 23, 2020, with docket number P2495-USP; and US provisional application no. 63/126,379 entitled “Genetically Engineered Phagocytes and Related Compositions Methods and Systems” filed on December 16, 2020, with docket number P2495-USP2. A provisional patent application entitled “Suppression of Neurodegeneration with the Zinc Transporter ZIP7” UCSB-546PRV_UC2022–758–1_ST25, was filed on September 13, 2021. D.J.M. has received research funds in the form of unrestricted gifts from the Anastasis Biotechnology Corporation and from Inceptor Bio. M.N. declares no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources